[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,298,568
  • Shares Outstanding, K 576,857
  • Annual Sales, $ 2,378 M
  • Annual Income, $ 770,950 K
  • EBIT $ 1,560 M
  • EBITDA $ 1,592 M
  • 60-Month Beta 0.40
  • Price/Sales 12.18
  • Price/Cash Flow 10.51
  • Price/Book 2.91

Options Overview Details

View History
  • Implied Volatility 27.01% (-1.36%)
  • Historical Volatility 20.22%
  • IV Percentile 6%
  • IV Rank 14.16%
  • IV High 75.80% on 01/14/26
  • IV Low 18.96% on 05/21/25
  • Expected Move (DTE 5) 1.24 (2.44%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 154
  • Volume Avg (30-Day) 101
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 9,521
  • Open Int (30-Day) 10,978
  • Expected Range 49.55 to 52.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.27
  • Number of Estimates 4
  • High Estimate $1.29
  • Low Estimate $1.26
  • Prior Year $1.14
  • Growth Rate Est. (year over year) +11.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.44 +7.07%
on 04/09/26
51.65 -1.67%
on 05/06/26
+2.89 (+6.03%)
since 04/08/26
3-Month
42.50 +19.51%
on 02/11/26
51.65 -1.67%
on 05/06/26
+6.14 (+13.75%)
since 02/06/26
52-Week
32.15 +57.98%
on 05/23/25
51.65 -1.67%
on 05/06/26
+17.69 (+53.44%)
since 05/08/25

Most Recent Stories

More News
Royalty Pharma to present at upcoming investor conferences

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: BofA...

RPRX : 50.79 (+1.18%)
Royalty Pharma reports first quarter 2026 results

Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance: Portfolio Receipts expected...

RPRX : 50.79 (+1.18%)
What Does Royalty Pharma's Revenue Forecast Say About the Royalty Model Itself?

Barchart Research What to Expect from RPRX Earnings RPRX Generated May 5, 2026 Current Price $50.44 EPS Estimate $$1.22 Consensus Rating Strong Buy Average Move 2.39% What Does Royalty Pharma's Revenue...

RPRX : 50.79 (+1.18%)
Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings

Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings

RPRX : 50.79 (+1.18%)
3 Unpopular Stocks We’re Skeptical Of

3 Unpopular Stocks We’re Skeptical Of

RPRX : 50.79 (+1.18%)
CSCO : 96.57 (+4.79%)
MOV : 28.01 (+1.52%)
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in translational...

RPRX : 50.79 (+1.18%)
Royalty Pharma Declares Second Quarter 2026 Dividend

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary...

RPRX : 50.79 (+1.18%)
Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026

NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S. financial...

RPRX : 50.79 (+1.18%)
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds

1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds

CORT : 52.28 (+2.41%)
RPRX : 50.79 (+1.18%)
SYK : 285.47 (-2.98%)
Branded Pharmaceuticals Stocks Q4 Teardown: Royalty Pharma (NASDAQ:RPRX) Vs The Rest

Branded Pharmaceuticals Stocks Q4 Teardown: Royalty Pharma (NASDAQ:RPRX) Vs The Rest

RPRX : 50.79 (+1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko...

See More

Key Turning Points

3rd Resistance Point 51.81
2nd Resistance Point 51.49
1st Resistance Point 51.14
Last Price 50.79
1st Support Level 50.47
2nd Support Level 50.15
3rd Support Level 49.80

See More

52-Week High 51.65
Last Price 50.79
Fibonacci 61.8% 44.20
Fibonacci 50% 41.90
Fibonacci 38.2% 39.60
52-Week Low 32.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.